Re: Question for the board!

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Question for the board!

in response to

Re: Question for the board!

narmac

posted on Jan 22, 2019 01:40PM

Also keep in mind the Resverlogix Royalty Preferred Shares (RPS) dynamic. Zenith Capital Corp (ZCC) holds the RPSs. Zenith Epigenetics Ltd (ZEL) is a subsidiary of ZCC. If I remember correctly, the re-organization that took place would allow ZEL to be listed or sold independent of ZCC. ZEL is the science side with the compounds and running the trials. My preferred scenario is for ZEL to be listed or sold but that I retain my shares of ZCC for potential royalty benefit.